kpv

tiny three-amino-acid peptide for inflammation. IBD, eczema, autoimmune. none of α-MSH's tanning or appetite side effects.

tier B · healing · picomolar NF-kB inhibition

verdict

a three-amino-acid fragment of alpha-MSH. preserves the anti-inflammatory tail without the tanning, appetite, or arousal effects.

if you're asking why KPV instead of full alpha-MSH — alpha-MSH drives pigmentation (MC1R), appetite suppression (MC4R), and arousal alongside its anti-inflammatory effect. KPV preserves the anti-inflammatory tail without the same melanocortin baggage. NF-kB inhibition in colonic epithelial cells, immune cells, and keratinocytes is the proposed mechanism. PepT1 upregulation in inflamed gut tissue is what makes oral KPV mechanistically interesting in gut models.

if you're asking about IBD, eczema, or post-surgical gut healing — this is what compounding-pharmacy KPV has been prescribed for under physician supervision. the preclinical evidence is substantial. DSS and TNBS colitis, transfer colitis, contact dermatitis, colitis-associated cancer. the human trial program is absent. clinical use runs on mechanism plus animal data plus practitioner reports, not on completed RCTs.

if you came in worried about the 'whole-body immune reset' framing — not supported by the mechanism. KPV is a localized anti-inflammatory tool. the FDA pulled KPV from 503A category 2 on April 22, 2026; PCAC reviews it July 23, 2026 alongside BPC-157, TB-500, and MOTS-c. public comment closes July 9, 2026. first formal regulatory review track, not authorization. plausible drug for mucosal anti-inflammatory use, unbuilt evidence base for the broader claims.

based on published evidence and disclosed clinical practice. not medical advice.

why B-tier

B-tier because the preclinical evidence is substantial and the mechanism is well-characterized, but human clinical trials are limited and U.S. compounding status is unsettled. KPV appears in combination blends like KLOW and has a coherent mucosal anti-inflammatory thesis, but it does not have phase 3 evidence or a formal approval pathway. Pharmacologically elegant, clinically underbuilt.

the core tension

KPV is an unusual case where a smaller molecule is genuinely cleaner than its larger parent. α-MSH has potent anti-inflammatory effects but also drives pigmentation, appetite, and arousal. Trimming down to just the three C-terminal amino acids preserves the inflammation-control idea while eliminating the other effects. The preclinical evidence for gut and skin inflammation is substantial. Human clinical trial data is limited, and U.S. compounding status is unsettled after FDA removed KPV from category 2 and slated it for PCAC review.

what it is

KPV is a tripeptide, lysine-proline-valine, the C-terminal fragment of alpha-melanocyte stimulating hormone. one of the smallest bioactive peptides in clinical research at 342 Da. small enough to be orally absorbed via the PepT1 di/tripeptide transporter, which is unusual for a peptide drug.

what it does

inhibits NF-kB activation in colonic epithelial cells, immune cells, and keratinocytes, reducing downstream inflammatory cytokine expression. PepT1 expression is upregulated in inflamed gut tissue, which makes oral KPV scientifically interesting in gut models. preclinical data covers DSS and TNBS colitis models, transfer colitis, contact dermatitis, and colitis-associated cancer.

origin

isolated as the anti-inflammatory active site of alpha-MSH during the 1990s as researchers across multiple labs dissected the parent hormone's effects. not a single-institution discovery. foundational PepT1 transport work was published in Gastroenterology by Dalmasso et al. in 2008. featured as a component of the KLOW blend in clinical-pharmacy practice.

why researchers are interested

rare case where the smaller fragment is genuinely cleaner than the parent. alpha-MSH drives pigmentation, appetite suppression, and arousal alongside its anti-inflammatory effect; KPV preserves the anti-inflammatory tail without the same melanocortin baggage. the elegance of the pharmacology is the appeal.

does it work

the mechanism is solid, the preclinical evidence is substantial, and the human trial program is absent. there are no phase-3 trials. some compounding pharmacies have dispensed KPV on physician prescription, with practitioners citing IBD, eczema, and post-surgical gut healing as targets, on the strength of mechanism plus animal data plus practitioner reports. none of those uses rests on completed human trials. the FDA pulled KPV from 503A category 2 on April 22, 2026; PCAC reviews it on July 23, 2026 alongside BPC-157, TB-500, and MOTS-c on Day 1 of the meeting. Public comment closes July 9, 2026. First formal regulatory review track but not authorization. the case for mucosal anti-inflammatory use is honest. the case for 'whole-body immune reset' that some marketing pushes is not supported by the mechanism. plausible drug, unbuilt evidence base.

claims vs the data

• suppresses NF-κB activation across multiple cell types — supported — Well-documented across cell-culture studies in colonic epithelial cells, immune cells, and keratinocytes. KPV inhibits NF-κB translocation to nucleus, reducing downstream inflammatory cytokine expression. Mechanism is established.
• reduces inflammation in IBD models — supported — Multiple mouse studies in DSS-induced and TNBS-induced colitis demonstrate decreased inflammatory markers, reduced weight loss, and histologic improvement. Translation through PepT1 transporter enables oral delivery, which is unusual and valuable for a peptide.
• preserves immune function (not broadly immunosuppressive) — partially true — Mechanism suggests targeted NF-κB suppression rather than broad immune shutdown. Preclinical data consistent with this. Long-term human data doesn't exist at scale to fully characterize immune effects with chronic use.
• effective for inflammatory skin conditions — weak — Preclinical evidence in models of contact dermatitis and inflammatory skin disease. Human clinical evidence is limited to small case series and clinic reports. Mechanistically plausible.
• FDA-approved or in regulatory pipeline — contradicted — No FDA approval. No active IND or clinical trial program advancing KPV through drug review. FDA's 2026 PCAC discussion is a compounding-status question, not a therapeutic-approval pathway.
• safer than corticosteroids for chronic inflammation — partially true — No HPA-axis suppression, no skin thinning, no bone density effects. Theoretical advantage for long-term use. But corticosteroids have decades of safety data; KPV does not. Claim is mechanistically reasonable but not clinically validated.

key facts

• molecular formula: C16H30N4O4
• molecular weight: 342.4 Da
• amino acids: 3
• half-life: short in plasma; stable in GI tract (unusual for a peptide, supports oral delivery)
• type: tripeptide (α-MSH C-terminal fragment)
• CAS: 67727-97-3
• 3 amino acids, smallest peptide on this list
• NF-κB primary inhibition target
• PepT1 transport mechanism studied in gut models
• ~0 phase 3 human clinical trials completed

frequently asked questions

What is KPV?

KPV is a tripeptide (Lysine-Proline-Valine), the C-terminal fragment of α-MSH (alpha-melanocyte stimulating hormone). It retains the anti-inflammatory activity of the parent hormone without the melanogenic effects that drive tanning.

What does KPV do?

KPV has demonstrated potent anti-inflammatory effects in preclinical models of inflammatory bowel disease, skin inflammation, and wound healing. It appears to act through NF-κB pathway inhibition and mast cell stabilization. Community users report benefits for gut inflammation, IBS symptoms, and skin conditions.

How is KPV typically administered?

Preclinical and market use discuss oral, topical, and injectable routes depending on target tissue, but no route has an FDA-approved dosing framework. The oral gut story is plausible because of PepT1 model data; it is not the same thing as a completed human exposure and efficacy package.

What are the side effects of KPV?

Community reports are usually mild, but formal human safety characterization is thin. The tripeptide structure is reassuring at the mechanism level, not a substitute for route-specific safety data.

Is KPV FDA approved?

No. KPV has no FDA approval. FDA removed KPV from category 2 after the nomination was withdrawn and plans PCAC review on July 23, 2026. That review is not authorization, and KPV does not have a clean routine U.S. compounding lane.

How much does KPV cost?

No clinical retail price. Compounded KPV from hormone clinics is sold as a monthly package. On the research-chemical market it is lower cost than most peptides due to synthesis simplicity.

related peptides

• klow — KPV is one of the four components of KLOW
• bpc-157 — commonly stacked for gut healing + inflammation
• melanotan-ii — full α-MSH analog, related mechanism with broader effects

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.